Cardinal Atones for Its Sins

Recs

1

Motley Fool Stock Advisor

Since 2002, David and Tom Gardner have returned 26.63% while the S&P 500 returned -12.56%. Try Stock Advisor free for 30 days.

Stock Advisor

For companies in the drug industry, there's one agency that they'd rather not deal with: the Drug Enforcement Administration. Those guys have guns, you know.

Cardinal Health (NYSE: CAH) thinks it's finally done dealing with the agency, now that it has agreed to pay a $34 million fine. The DEA has agreed to reinstate the company's licenses to distribute controlled substances at three distribution centers.

The licenses were revoked because Cardinal didn't report suspicious purchases of hydrocodone that it distributed to pharmacies that filled fake prescriptions from Internet pharmacies. The company has since spent $20 million to upgrade its system, in hopes of avoiding trouble with the DEA again.

Cardinal isn't the only drug distributor that's had problems with the DEA recently. Both of its main competitors, McKesson (NYSE: MCK) and AmerisourceBergen, (NYSE: ABC) have also resolved issues with the agency over the distribution of controlled substances. It seems rather ridiculous to me that the DEA requires the companies to play the role of a police officer, but if they want a license to deal drugs, I guess they have to play by the rules.

These DEA crackdowns on the abuse of prescription drugs could help the likes of Pain Therapeutics (Nasdaq: PTIE), King Pharmaceuticals (NYSE: KG) and Alpharma (NYSE: ALO) -- drugmakers that are developing abuse-deterrent drugs. The Food and Drug Administration isn't likely to approve these drugs just because the DEA says they're needed, but once the harder-to-abuse drugs are approved, everyone in the supply chain is likely to encourage their use, if it means lowering the chances of getting in trouble with the DEA -- and its guns.

It's certainly good news for Cardinal and its investors that the DEA issue is behind it. Now it can focus on that spinoff it announced a short time ago.

More Foolishness:

Follow along with the Global Gains team as they travel to key business centers in China to uncover the very best investing opportunities! Sign up here to receive their FREE dispatches from the road.

Let us know what you think about this stock in Motley Fool CAPS. Make an outperform or underperform call on the four-star Cardinal Health, and post a pitch about whether you think the reinstated licenses will help or not. It's free. It's fun. And, it's Foolish. 

Fool contributor Brian Orelli, Ph.D., doesn't own shares of any company mentioned in this article. The Fool has a disclosure policy.

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

TD AMERITRADE
more info
ShareBuilder
more info
Power E*Trade

more info
Scottrade
more info
Fool Disclosure

DocumentId: 745565, ~/articles/ArticleHandler.aspx, 7/11/2009 1:27:08 PM

Keep Reading:

“Cardinal Atones for Its Sins”

We will use your email address only to keep you informed about updates to our web site and about other products and services that we think might interest you. The Motley Fool respects your privacy. Please read our Privacy Statement

.

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

What Fools Are Saying

Get involved! »

Most Recent

Jul 10 at 4:03 PM

Market Summary

DJIA 8,146.52 -36.65 -0.45%
S&P 500 879.13 -3.55 -0.40%
NASD 1,756.03 +3.48 +0.20%
Sponsored by:

Related Tickers

Cardinal Health, Inc.

CAPS Rating 4/5 Stars

$29.33

-0.37 (-1.25%)

Outperform320

Underperform31

Rate This Stock